

Male Oxidative Stress Infertility (MOSI)

Agarwal, Ashok; Kirkman-Brown, Jackson

DOI:

[10.5534/wjmh.190055](https://doi.org/10.5534/wjmh.190055)

License:

Creative Commons: Attribution-NonCommercial (CC BY-NC)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Agarwal, A & Kirkman-Brown, J 2019, 'Male Oxidative Stress Infertility (MOSI): proposed terminology and clinical practice guidelines for management of idiopathic male infertility', *World Journal of Men's Health*, vol. 37, no. 3, pp. 296-312. <https://doi.org/10.5534/wjmh.190055>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Agarwal, A. et al (2019) Male Oxidative Stress Infertility MOSI proposed terminology and clinical practice guidelines for management of idiopathic male infertility, *World Journal of Men's Health*, volume 37, issue 3, pages 296-312, <https://doi.org/10.5534/wjmh.190055>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility

Ashok Agarwal^{1,2}, Neel Parekh², Manesh Kumar Panner Selvam^{1,2}, Ralf Henkel^{1,3}, Rupin Shah⁴, Sheryl T. Homa⁵, Ranjith Ramasamy⁶, Edmund Ko⁷, Kelton Tremellen⁸, Sandro Esteves^{9,10}, Ahmad Majzoub^{1,11}, Juan G. Alvarez¹², David K. Gardner¹³, Channa N. Jayasena^{14,15}, Jonathan W. Ramsay¹⁵, Chak-Lam Cho¹⁶, Ramadan Saleh¹⁷, Denny Sakka¹⁸, James M. Hotaling¹⁹, Scott D. Lundy², Sarah Vij², Joel Marmar²⁰, Jaime Gosalvez²¹, Edmund Sabanegh², Hyun Jun Park^{22,23}, Armand Zini²⁴, Parviz Kavoussi²⁵, Sava Micic²⁶, Ryan Smith²⁷, Gian Maria Busetto²⁸, Mustafa Emre Bakircioglu²⁹, Gerhard Haidl³⁰, Giancarlo Balercia³¹, Nicolás Garrido Puchalt³², Moncef Ben-Khalifa³³, Nicholas Tadros³⁴, Jackson Kirkman-Browne^{35,36}, Sergey Moskovtsev³⁷, Xuefeng Huang³⁸, Edson Borges Jr³⁹, Daniel Franken⁴⁰, Natan Bar-Chama⁴¹, Yoshiharu Morimoto⁴², Kazuhisa Tomita⁴², Vasan Satya Srin⁴³, Willem Ombelet^{44,45}, Elisabetta Baldi⁴⁶, Monica Muratori⁴⁷, Yasushi Yumura⁴⁸, Sandro La Vignera⁴⁹, Raghavender Kosgi⁵⁰, Marlon P. Martinez⁵¹, Donald P. Evenson⁵², Daniel Suslik Zylbersztejn⁵³, Matheus Roque⁵⁴, Marcello Cocuzza⁵⁵, Marcelo Vieira^{56,57}, Assaf Ben-Meir⁵⁸, Raoul Orvieto^{59,60}, Eliahu Levitas⁶¹, Amir Wiser^{62,63}, Mohamed Arafa⁶⁴, Vineet Malhotra⁶⁵, Sijo Joseph Parekattil^{66,67}, Haitham Elbardisi⁶⁴, Luiz Carvalho^{68,69}, Rima Dada⁷⁰, Christophe Sifer⁷¹, Pankaj Talwar⁷², Ahmet Gudeloglu⁷³, Ahmed M.A. Mahmoud⁷⁴, Khaled Terras⁷⁵, Chadi Yazbeck⁷⁶, Bojanic Nebojsa⁷⁷, Damayanthi Durairajanayagam⁷⁸, Ajina Mounir⁷⁹, Linda G. Kahn⁸⁰, Saradha Baskaran¹, Rishma Dhillon Pai⁸¹, Donatella Paoli⁸², Kristian Leisegang⁸³, Mohamed-Reza Moein⁸⁴, Sonia Malik⁸⁵, Onder Yaman⁸⁶, Luna Samanta⁸⁷, Fouad Bayane⁸⁸, Sunil K. Jindal⁸⁹, Muammer Kendirci⁹⁰, Baris Altay⁹¹, Dragoljub Perovic⁹², Avi Harlev⁹³

¹American Center for Reproductive Medicine, Cleveland Clinic, ²Department of Urology, Cleveland Clinic, Cleveland, OH, USA, ³Department of Medical Bioscience, University of the Western Cape, Cape Town, South Africa, ⁴Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India, ⁵School of Biosciences, University of Kent, Canterbury, UK, ⁶Department of Urology, University of Miami, Miami, FL, ⁷Department of Urology, Loma Linda University Health, Loma Linda, CA, USA, ⁸Department of Obstetrics Gynaecology and Reproductive Medicine, Flinders University, Bedford Park, Australia, ⁹Division of Urology, Department of Surgery, University of Campinas (UNICAMP), Campinas, Brazil, ¹⁰Faculty of Health, Aarhus University, Aarhus, Denmark, ¹¹Department of Urology, Hamad Medical Corporation and Weill Cornell Medicine-Qatar, Doha, Qatar, ¹²Centro Androgen, La Coruña, Spain and Harvard Medical School, Boston, MA, USA, ¹³School of BioSciences, University of Melbourne, Parkville, Australia, ¹⁴Section of Investigative Medicine, Imperial College London, ¹⁵Department of Andrology, Hammersmith Hospital, London, UK, ¹⁶Department of Surgery, Union Hospital, Shatin, Hong Kong, ¹⁷Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt, ¹⁸Boston IVF, Waltham, MA, ¹⁹Department of Urology, University of Utah, Salt Lake City, UT, ²⁰Cooper University Hospital, Camden, NJ, USA, ²¹Departamento de Biología, Universidad Autónoma de Madrid, Madrid, Spain, ²²Department of Urology, Pusan National University School of Medicine, ²³Medical Research Institute of Pusan National University Hospital, Busan, Korea, ²⁴Department of Surgery, McGill

Received: Apr 2, 2019 Accepted: Apr 2, 2019 Published online May 8, 2019

Correspondence to: Ashok Agarwal <https://orcid.org/0000-0003-0585-1026>

American Center for Reproductive Medicine, Cleveland Clinic, Mail Code X-11, 10681 Carnegie Avenue, Cleveland, OH 44195, USA.

Tel: +1-216-444-9485, Fax: +1-216-445-6049, E-mail: agarwaa@ccf.org, Website: CCF.org/ReproductiveResearchCenter

University, Montreal, QC, Canada, ²⁵Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, USA, ²⁶Uromedica Polyclinic, Kneza Milosa, Belgrade, Serbia, ²⁷Department of Urology, University of Virginia, Charlottesville, VA, USA, ²⁸Sapienza University of Rome, Rome, Italy, ²⁹Istanbul Florence Nightingale Hospital, Istanbul, Turkey, ³⁰Department of Dermatology, University Hospital Bonn, Bonn, Germany, ³¹Division of Endocrinology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Umberto I Hospital, Ancona, Italy, ³²IVI Foundation Edificio Biopolo – Instituto de Investigación Sanitaria la Fe, Valencia, Spain, ³³University Hospital, School of Medicine and PERITOX Laboratory, Amiens, France, ³⁴Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA, ³⁵Centre for Human Reproductive Science, IMSR, College of Medical & Dental Sciences, The University of Birmingham Edgbaston, ³⁶The Birmingham Women's Fertility Centre, Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Drive, Edgbaston, UK, ³⁷Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada, ³⁸Reproductive Medicine Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ³⁹Fertility Medical Group, São Paulo, Brazil, ⁴⁰Department of Obstetrics & Gynecology, Andrology Unit Faculties of Health Sciences, Tygerberg Hospital, Tygerberg, South Africa, ⁴¹Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁴²IVF Japan Group, Horac Grand Front Osaka Clinic, Osaka, Japan, ⁴³Manipal Fertility, Bangalore, India, ⁴⁴Genk Institute for Fertility Technology, Genk, ⁴⁵Hasselt University, Biomedical Research Institute, Diepenbeek, Belgium, ⁴⁶Department of Experimental and Clinical Medicine, Center of Excellence DeNothe, University of Florence, ⁴⁷Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Unit of Sexual Medicine and Andrology, Center of Excellence DeNothe, University of Florence, Florence, Italy, ⁴⁸Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan, ⁴⁹Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, ⁵⁰Androbest Andrology & Urology Center, Hyderabad, India, ⁵¹Section of Urology, University of Santo Tomas Hospital, Manila, Philippines, ⁵²SCSA Diagnostics, Brookings, SD, USA, ⁵³Fleury Group and Hospital Israelita Albert Einstein, São Paulo, ⁵⁴Origen, Center for Reproductive Medicine, Rio de Janeiro, ⁵⁵Department of Urology, University of São Paulo (USP), ⁵⁶Division of Urology, Infertility Center ALFA, São Paulo, ⁵⁷Head of Male Infertility Division, Andrology Department, Brazilian Society of Urology, Rio de Janeiro, Brazil, ⁵⁸Fertility and IVF Unit, Department of Obstetrics and Gynecology, Hebrew-University Hadassah Medical Center, Jerusalem, ⁵⁹Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, ⁶⁰Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, ⁶¹Soroka University Medical Center, Ben-Gurion University of the Negev Beer-Sheva, Beersheba, ⁶²IVF Unit, Meir Medical Center, Kfar Sava, ⁶³Sackler Medicine School, Tel Aviv University, Tel Aviv, Israel, ⁶⁴Department of Urology, Hamad Medical Corporation, Doha, Qatar, ⁶⁵Department of Andrology and Urology, Diyos Hospital, New Delhi, India, ⁶⁶PUR Clinic, South Lake Hospital, Clermont, ⁶⁷University of Central Florida, Orlando, FL, USA, ⁶⁸Baby Center, Institute for Reproductive Medicine, ⁶⁹College Institute of Clinical Research and Teaching Development, São Paulo, Brazil, ⁷⁰Lab for Molecular Reproduction and Genetics, Anatomy, All India Institute of Medical Sciences, New Delhi, India, ⁷¹Department of Reproductive Biology, Hôpitaux Universitaires Paris Seine Saint-Denis, Bondy, France, ⁷²Department of Reproductive Medicine and Embryology, Manipal Hospital, New Delhi, India, ⁷³Department of Urology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁷⁴Department of Endocrinology/Andrology, University Hospital Ghent, Ghent, Belgium, ⁷⁵Department of Reproductive Medicine, Hannibal International Clinic, Tunis, Tunisia, ⁷⁶Department of Obstetrics, Gynecology and Reproductive Medicine, Pierre Cherest and Hartman Clinics, Paris, France, ⁷⁷Clinic of Urology, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, ⁷⁸Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Selangor, Malaysia, ⁷⁹Department of Embryology, Faculty of Medicine, University of Sousse, Sousse, Tunisia, ⁸⁰Department of Pediatrics, New York University School of Medicine, New York, NY, USA, ⁸¹Department of Obstetrics and Gynaecology, Lilavati Hospital and Research Centre, Mumbai, India, ⁸²Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, ⁸³School of Natural Medicine, University of the Western Cape, Cape Town, South Africa, ⁸⁴Department of Andrology, Shahid Sadoughi Medical University, Yazd, Iran, ⁸⁵Southend Fertility & IVF, Delhi, India, ⁸⁶Department of Urology, School of Medicine, University of Ankara, Ankara, Turkey, ⁸⁷Redox Biology Laboratory, Department of Zoology and Center of Excellence in Environment and Public Health, Ravenshaw University, Cutrack, India, ⁸⁸Marrakech Fertility Institute, Marrakech, Morocco, ⁸⁹Jindal Hospital, Meerut, India, ⁹⁰Department of Urology, Istinye University Faculty of Medicine, Liv Hospital Ulus, Istanbul, ⁹¹Department of Urology, Ege University School of Medicine, İzmir, Turkey, ⁹²Center of Urology, CODRA Hospital, Podgorica, Montenegro, ⁹³Fertility and IVF Unit, Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel

Despite advances in the field of male reproductive health, idiopathic male infertility, in which a man has altered semen characteristics without an identifiable cause and there is no female factor infertility, remains a challenging condition to diagnose and manage. Increasing evidence suggests that oxidative stress (OS) plays an independent role in the etiology of male infertility, with 30% to 80% of infertile men having elevated seminal reactive oxygen species levels. OS can negatively affect fertility via a number of pathways, including interference with capacitation and possible damage to sperm membrane and DNA, which may impair the sperm's potential to fertilize an egg and develop into a healthy embryo. Adequate evaluation of male reproductive potential should therefore include an assessment of sperm OS. We propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, including many patients who were previously classified as having idiopathic male infertility. Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants). Current treatment protocols for OS, including the use of antioxidants, are not evidence-based and have the potential for complications and increased healthcare-related expenditures. Utilizing an easy, reproducible, and cost-effective

test to measure ORP may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose. With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, future research endeavors can facilitate the development of evidence-based treatments that target its underlying cause.

Keywords: Infertility, male; MOSI; Oxidation reduction potential; Oxidative stress; Semen

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Natural conception is a complex process that is achieved in only 76% to 85% of couples within 12 months of regular unprotected intercourse [1-5]. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) defines infertility as the inability to conceive after 1 year of regular, unprotected intercourse [6,7]. The World Health Organization estimates that nearly 190 million people struggle with infertility worldwide and the number of couples seeking medical assistance is steadily rising [8,9]. Among couples unable to conceive, infertility is partially or wholly attributable to a male factor in approximately 50% of cases (Fig. 1) [10-12]. A variety of conditions can affect male reproductive potential to different extent and they often coexist (Fig. 2) [13-19]. Paradoxically, on routine assessment, the precise etiology of male factor infertility remains undefined in 30% to 50% of patients, who are subsequently classified as having




Fig. 2. Conditions affecting male reproductive potential.




Fig. 1. World map containing percentages of infertility cases per region that are due to male factor involvement among regions studied. Asia includes all of Russia. Data from Agarwal et al (Reprod Biol Endocrinol 2015;13:37) [10].

idiopathic male infertility [20-22]. Unlike unexplained male infertility with its normal semen parameters, idiopathic male infertility is diagnosed in the presence of altered semen characteristics without an identifiable cause and the absence of female factor infertility [23].

THE CONCEPT OF MALE OXIDATIVE STRESS INFERTILITY (MOSI)

There is overwhelming evidence that oxidative stress (OS) plays a significant role in the etiology of male infertility [24-30]. Seminal reactive oxygen species (ROS) are produced mainly by leukocytes or abnormal and immature spermatozoa, and are a natural byproduct of oxidative metabolic pathways as well as cytosolic and plasma membrane oxidases [31-34]. ROS are also a natural byproduct of adenosine triphosphate production within sperm cell mitochondria [35]. Small quantities of ROS are required to ensure normal cellular physiological functions, including spermatogenesis and various sperm functions preceding fertilization, such as capacitation and acrosome reaction [32,36-38]. When ROS levels increase to a pathological level, the body uses dietary and endogenously produced antioxidants to bring the system back to homeostasis [39]. An imbalance between these two opposing forces, in which ROS outweigh antioxidants, can result in OS, which can negatively affect fertility *via* a number of pathways. OS interferes with capacitation and may cause sperm membrane and DNA damage, thereby affecting the sperm's potential to fertilize an egg and generate

a healthy embryo [32,40-45]. Also, OS can trigger formation of genotoxic and mutagenic byproducts in the sperm that may increase the risk of disease in the offspring [46]. Depending on the assay methodology used, recent literature suggests that 30% to 80% of infertile men have elevated seminal ROS levels, a potentially treatable condition [28,30,44,47-56]. A similarly high incidence of OS was reported in a recent clinical trial, with 83.8% (124 of 148 cases) of idiopathic infertile men having positive seminal oxidation-reduction potential (ORP), a measure of ROS-antioxidant discrepancy [unpublished data].

Male reproductive potential cannot be adequately assessed if seminal OS is overlooked. However, there is currently no consensus concerning either the preferred method to measure OS in the clinical setting nor the diagnostic terminology to define this condition. Therefore, we propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, which includes many patients who were previously classified as having idiopathic male infertility (Appendix) [24,52,57-59]. Based on several epidemiologic studies, OS may be present in about 56 million males complaining of infertility, two-thirds of whom are considered to have MOSI (<https://www.nichd.nih.gov/health/topics/menshealth/conditioninfo/infertility>) (Fig. 3) [30,60-63]. In men with normal semen characteristics who are part of couples experiencing unexplained infertility, the role of OS is not well defined. In our experience, 29.4% (10 of 34) of men in this group have leukocytospermia as opposed to




Fig. 3. Worldwide incidence of MOSI in infertile men. ^aNational Institutes of Health (NIH) (<https://www.nichd.nih.gov/health/topics/menshealth/conditioninfo/infertility>) [61], Agarwal et al (2014) [60], Jarow et al (2011) [63].

12.2% (77 of 629) in the general population of men with infertility [unpublished data].

DIAGNOSIS OF MALE OXIDATIVE STRESS INFERTILITY (MOSI)

Conventional semen analysis was introduced about a century ago and remains the most widely used test for measuring sperm production and quality. In recent years, it has become clear that conventional semen analysis alone is not an adequate surrogate measure of male fecundity [64], as it is plagued with critical shortcomings such as poor reproducibility, subjectivity, and poor prediction of fertility [65-68]. Given the limited clinical utility of conventional semen analysis and the pathological consequences and ubiquity of OS among the subfertile male population, we propose the incorporation of ORP as a useful clinical biomarker for MOSI in men with abnormal semen analysis and male infertility [58,69-72]. ORP may be used to measure the levels of reductants (antioxidants) and oxidants in a variety of biological fluids [73] and could become an adjunct component of semen analysis due to its robust association with impaired sperm function. A number of assays are available to measure OS including chemiluminescence for ROS, total antioxidant capacity for an-

tioxidants, and the malondialdehyde assay for post-hoc damage from lipid peroxidation [74-76]. Though useful, these tests are difficult to incorporate into routine use because they are expensive, complex, and time-sensitive, and may also require complex instrumentation, large and neat sample volumes, and extensive technical training (Table 1) [76]. Additionally, assay results do not correlate with one another and provide only a single marker of OS-either oxidant levels, antioxidant levels, or post-hoc damage [77].

To date, measurement of ROS in semen is not often utilized as, depending on the method for ROS assessment, it may be prone to intra- and inter-laboratory variability, high turnaround time and high costs [58,69,78]. The advent of new technologies that rapidly detect seminal OS through the assessment of ORP in a reproducible manner using a bench-top analyzer can allow for an accurate and cost-effective diagnosis of MOSI [76,78,79]. The Male Infertility Oxidative System (MiOXSYS) is a recently developed assay for the assessment of ORP [69]. The ORP test is novel in the area of infertility and is based on a galvanostatic measure of electrons. MiOXSYS has been developed for easy and quick measurement of ORP in semen [80]. Several studies have validated the reproducibility and reliability of the MiOXSYS in measuring ORP levels in semen

Table 1. Advantages and disadvantages of commonly used techniques to measure seminal oxidative stress

Assay	Advantages	Disadvantages
ROS by chemiluminescence	<ul style="list-style-type: none"> Chemiluminescence is robust High sensitivity and specificity Luminol measures global ROS levels – both extracellular and intracellular (superoxide anion, hydrogen peroxide, hydroxyl radical) 	<ul style="list-style-type: none"> Time-consuming method Requires large and expensive equipment Variables such as semen age, volume, repeated centrifugation, temperature control and background luminescence may interfere with measurement
TAC	<ul style="list-style-type: none"> Rapid colorimetric method Measures total antioxidants in seminal plasma 	<ul style="list-style-type: none"> Does not measure enzymatic antioxidants Length of inhibition time is a critical aspect of the test Requires expensive microplate readers
ROS-TAC score	<ul style="list-style-type: none"> Better predictor compared with ROS or TAC alone 	<ul style="list-style-type: none"> Requires statistical modeling Not a direct measure of ROS or TAC, rather a prediction of oxidative stress
MDA-TBA adduct detection by colorimetry or fluoroscopy	<ul style="list-style-type: none"> Measures lipid peroxidation Detects MDA-TBA adduct by colorimetry or fluoroscopy 	<ul style="list-style-type: none"> Rigorous controls required Non-specific test providing post hoc measure only
ORP	<ul style="list-style-type: none"> Provides redox balance in real time Measures all known and unknown oxidants and antioxidants Less time-consuming and requires less expertise Can be measured in semen and seminal plasma, including frozen specimens 	<ul style="list-style-type: none"> Affected by viscosity of the sample

ROS: reactive oxygen species, TAC: total antioxidant capacity, MDA: malondialdehyde, TBA: thiobarbituric acid, ORP: oxidation-reduction potential. Data from Agarwal et al (Ther Adv Urol 2016;8:302-18) [76].

samples from patients being evaluated for male infertility [58,69,71,81]. More importantly, ORP levels have been shown to be significantly negatively correlated with sperm concentration, sperm motility, normal morphology and total motile count [72]. ORP levels are also significantly positively correlated with sperm DNA fragmentation (SDF) [72,79,81], although normal levels of SDF do not exclude the presence of OS. At a cut-off value of 1.34 (mV/10⁶ sperm/mL), ORP may be used to differentiate between normal and abnormal semen quality in infertile men with 98.1% sensitivity, 40.6% specificity, 94.7% positive predictive value, and 66.6% negative predictive value [58,59,69] (Fig. 4).

Among infertile men, higher ORP levels are observed

in cases with abnormal semen parameters *versus* normal parameters (Fig. 5A, 5B). Analysis of data of 3,966 patients at Hamad Medical Corporation, Doha, Qatar, revealed statistically significant negative correlations between ORP and normal sperm morphology ($r=-0.529$, $p<0.0001$), progressive motility ($r=-0.463$, $p<0.0001$), and sperm concentration ($r=-0.844$, $p<0.0001$). The difference in ORP between normozoospermic (mean: 1.14 ± 0.97 mV/10⁶ sperm/mL; median: 0.86 mV/10⁶ sperm/mL) and non-normozoospermic (mean: 5.65 ± 11.34 mV/10⁶ sperm/mL; median: 2.04 mV/10⁶ sperm/mL) patients was also significant ($p<0.0001$) (Fig. 5B). Fig. 5C depicts ORP values of asthenozoospermic (mean: 5.63 ± 11.36 mV/10⁶ sperm/mL; median: 2.03 mV/10⁶ sperm/mL) *versus* non-




Fig. 4. (A) A receiver operating characteristic (ROC) curve was used to identify the oxidation-reduction potential (ORP) (mV/10⁶ sperm/mL) cutoff that best predicted normal and abnormal semen parameters based on sensitivity (Sens), specificity (Spec), positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC). (B) Distribution of ORP in patients with at least one abnormal semen parameter *versus* patients with normal semen parameters, showing the established cutoff value of 1.34 mV/10⁶ sperm/mL. Data from Agarwal et al (Asian J Androl 2019 [in press]) [59].




Fig. 5. Distribution of oxidation-reduction potential (ORP) values in the infertile men with normal and abnormal semen parameters. (A) Data from Cleveland Clinic, Cleveland OH, USA (n=807); (B) Data from Hamad Medical Corporation, Doha, Qatar (n=3,966); (C) Data of asthenozoospermic patients from Hamad Medical Corporation, Doha, Qatar (n=3,966).

asthenozoospermic patients (mean: 1.79 ± 3.80 mV/ 10^6 sperm/mL; median: 0.92 mV/ 10^6 sperm/mL) [unpublished data].

MANAGEMENT AND TREATMENT OF MALE OXIDATIVE STRESS INFERTILITY (MOSI)

Despite significant advances in the diagnosis and management of male infertility, there are no evidence-based treatment guidelines available for idiopathic male infertility. Understandably, it is difficult to develop an evidence-based approach for a condition with

an unclear etiology. A survey among members of the American Urological Association (AUA) indicated that two-thirds of clinicians use empirical medical therapy (EMT) such as selective estrogen receptor modulators, aromatase inhibitors, and gonadotropins to treat idiopathic male factor infertility [82]. While the role of hormonal therapy in men with an identified abnormality such as hypogonadotropic hypogonadism is well-defined [83], endocrine imbalance is responsible for approximately 10% of all known causes of infertility [21]. The literature remains inconclusive and controversial regarding off-label EMTs for men with idiopathic infertility [20,82,84-87], especially in light of their cost

Table 2. Empiric medical treatment for idiopathic male infertility (ICD10 Code: Z31.41)

Medication	Administration	Common dosages	Adverse effects	Estimated cost per 3 months
Selective estrogen receptor modulators				
Clomiphene citrate ^a	Oral	50 mg daily	Hot flashes, weight gain, gynecomastia, hair loss, dizziness, gastrointestinal distress	\$185.40 ^c
Tamoxifen citrate ^a	Oral	20 mg daily	See above	\$99.60 ^c
Aromatase inhibitors				
Anastrozole ^a	Oral	1 mg, 3 times/wk	Decreased libido, headache, elevated liver function tests	\$35.40 ^c
Human chorionic-gonadotropin ^b	Subcutaneous	1,500–3,000 IU, 3 times/wk	Injection site pain, headache, depression, gynecomastia, hyperglycemia	\$337.50–\$675.00 ^d
Recombinant follicle-stimulating hormone ^b	Subcutaneous	75 IU, 3 times/wk	Injection site pain	\$2,160.00 ^d

^aOff label use; ^bFood and Drug Administration approved for treatment of infertility secondary to gonadotropin deficiency; ^cAverage cost at Walmart, CVS and Walgreens; ^dCompound pharmacy cost.

Table 3. Antioxidant classification in relation to its action on sperm characteristics

Type	Function	References
Enzymatic:		
Superoxide dismutase	First line defense antioxidants	[94,95]
Catalase	First line defense antioxidants	[54,96]
Glutathione peroxidase	Scavenges lipid peroxides and hydrogen peroxide	[97,98]
Glutathione reductase	Scavenges lipid peroxides and hydrogen peroxide	[99]
Non enzymatic:		
Vitamin C	Neutralizes free radicals	[100,101]
Vitamin E	Neutralizes free radicals	[102,103]
Ferritin and carnitines	Neutralizes free radicals and acts as an energy source	[126]
Coenzyme Q10	In its reduced form, scavenges free radicals intermediate in mitochondrial electron transport system	[104]
Transferrin	Sperm vitality, DNA integrity and OS homeostasis	[105]
Zinc	Formation of free oxygen radicals and sperm chromatin stability	[106]
Selenium	Sperm motility and OS homeostasis	[107]
N-acetyl L-cysteine	Free radical scavenging activity	[108,109]
L-arginine	Formation of free oxygen radicals	[110]
Folic acid	Sperm DNA integrity	[111]

OS: oxidative stress.

and side effects (Table 2). Although there are several small studies that provide support for pharmacological EMT to treat idiopathic male infertility, there is a lack of robust placebo-controlled trials demonstrating improved live birth outcomes [87-90].

For the vast majority of infertile men with no underlying endocrine, bacterial, genetic or anatomical causes of infertility, an alternative approach may be to shift from administering EMTs to identifying potential sources of MOSI and mitigating the sequela. The human body produces endogenous antioxidants in an effort to prevent the damage caused by ROS [91,92], but this response is not always adequate, resulting in OS. Several studies have shown that exogenous antioxi-

dants have the capacity to counteract oxidative damage or OS, improving both sperm motility and DNA integrity for infertile men with OS (Table 3) [87-91,93-111]. Indeed, many oral formulations of antioxidants are readily available in the market and are commonly used to treat men with infertility. However, there is growing awareness that the indiscriminate use of antioxidants may paradoxically exacerbate sperm cell damage in men without elevated MOSI by inducing a state of reductive stress [52,112]. In order to prevent the inappropriate use of antioxidants, clinical guidelines outlining the effective diagnosis and treatment of MOSI are critical. Several clinical trials and systemic reviews involving the use of various combinations of

Table 4. Effect of antioxidants on male infertility: Double blind placebo controlled studies^a

Study reference	Infertility type	Cases	Antioxidants	Duration	Outcome
Micic et al (2019) [119]	Idiopathic oligoasthenozoospermia	Placebo group (n=50) Treatment group (n=125)	Proxeed plus=2 times/d • LC=1,000 g, LAC=0.5 g, fumarate=0.725 g, fructose=1 g, citric acid=50 mg, zinc=10 mg, coenzyme Q10=20 mg, selenium=50 µg, Vit C=90 mg, folic acid=200 µg, Vit B12=1.5 µg	3 months	Increase in semen volume, progressive motility and vitality Decrease in sperm DNA fragmentation index
Busetto et al (2018) [113]	Idiopathic OAT, with and without varicocele	Varicocele (n=45) Without varicocele (n=49)	LC=1,000 mg, LAC=500 mg, fumarate=725 mg, fructose=1,000 mg, Coenzyme Q10=20 mg, Vit C=90 mg, Zinc=10 mg, folic acid=200 µg, Vit B12=1.5 µg	6 months	Increase in sperm concentration, total sperm count, motility, and progressive motility
Safarinejad et al (2012) [116]	Idiopathic infertility	Placebo group (n=114) Treatment group (n=114)	Coenzyme Q10=200 mg/d	26 weeks	Increase in sperm concentration, motility and normal sperm morphology
Safarinejad (2009) [114]	Idiopathic OAT	Placebo group (n=106) Treatment group (n=106)	Coenzyme Q10=300 mg/d	26 weeks	Increase in sperm concentration and motility
Balercia et al (2009) [120]	Idiopathic asthenozoospermia	Placebo group (n=30) Treatment group (n=30)	Coenzyme Q10=200 mg/d	3 months	Increase in sperm concentration and motility
Tremellen et al (2008) [28]	Male factor infertility	Placebo group (n=20) Infertile men (n=40)	Menevit=1 capsule/d • Lycopene=6 mg, Vit E=400 IU, Vit C=100 mg, Zinc=25 mg, selenium=26 µg, folate=0.5 mg, garlic=1,000 mg, palm oil (vehicle)	3 months	Improved pregnancy rates in couples undergoing IVF-ICSI treatment for severe male factor infertility
Balercia et al (2005) [115]	Idiopathic asthenozoospermia	Placebo group (n=15) Treatment group (n=45): LC group: n=15; LAC group: n=15; LC+LAC group: n=15	LC=3 g/d LAC=3 g/d LC+LAC=2 g+1 g/d	6 months	Increase in sperm motility and normal sperm morphology

OAT: oligoasthenoteratozoospermia, LC: L-carnitine, LAC: L-acetylcarnitine, Vit: vitamin, IVF-ICSI: *in vitro* fertilization/intracytoplasmic sperm injection. ^aOnly double blind placebo control studies on idiopathic male infertility patients were included. Except for three studies (94, 96, and 142), others used a combination of antioxidant supplements for a period of 3 to 6 months.

antioxidants (L-carnitine, selenium, N-acetyl-cysteine, Coenzyme Q10, ubiquinol, vitamin E, vitamin C, and lycopene) in infertile men have reported beneficial effects of antioxidants on sperm concentration, motility, and DNA integrity (Table 4) [113-120]. Preliminary results from a 2018 clinical trial involving 148 idiopathic infertile men indicated that intake of oral antioxidants for a period of three months significantly increased sperm concentration (36%, $p<0.0001$), progressive motility (100%, $p<0.0001$), and motility (12%, $p=0.0033$). Moreover, a significant decrease in ORP (39%, $p<0.0001$) and SDF (20%, $p=0.0002$) was observed post-treatment [unpublished data]. These beneficial changes in semen quality have been reported to improve the chance of natural conception in several but not all studies [53,121]. This benefit could be augmented, and harm prevented, by directing therapy through measuring and monitoring seminal ORP [113-116,122,123].

Identifying and treating MOSI in cases where the use of assisted reproductive technology (ART) is indicated is especially important, as many of the sperm preparation and handling methods used during ART may induce OS, further aggravating the negative impact of MOSI [124,125]. In couples undergoing ART, diagnosis of MOSI and subsequent antioxidant therapy may improve ART success [122,126,127]. Additionally, there is emerging evidence that antioxidant therapy may improve pregnancy outcomes in couples with recurrent pregnancy loss [128]. Evidence-based guidelines

should provide recommendations on ways to best manage other causes of OS, including lifestyle modifications (improved diet, smoking cessation, exercise, and weight loss), treatment of clinically relevant varicoceles, and treatment of male accessory gland infection (MAGI) as well as other inflammatory pathologies linked with MOSI (Fig. 3). The treatment of MAGI with antibiotics, and the decrease in the numbers of ROS-producing seminal leukocytes using anti-inflammatories are likely to add benefit in combination with neutralization of ROS by antioxidant therapy [129-132]. Treatment success and adherence for the above conditions can be monitored by measuring seminal ORP, as well.

The diagnosis and management of idiopathic male infertility is an integral component of comprehensive sexual and reproductive health services. Idiopathic male infertility can be an emotional burden and financial strain for couples. Current treatment protocols for male infertility are not evidence-based and have the potential risk of complications and increased healthcare-related expenditures [20,84]. MOSI provides clinicians and patients with a diagnostic classification to guide future research and treatment, while simultaneously reducing apprehension and uncertainty for many couples. A recent consensus guideline by the European Society for Human Reproduction & Embryology (ESHRE) concluded that there is currently insufficient evidence to support the use of antioxidants for male infertility due to lack of a standardized measure of OS




Fig. 6. Treatment options for male oxidative stress infertility. OS: oxidative stress, ORP: oxidation-reduction potential, MiOXSYS: Male Infertility Oxidative System, MAGI: male accessory gland infection, MOSI: Male Oxidative Stress Infertility.

and inconsistent selection of eligible patients across studies [133]. MOSI diagnosis combined with ORP monitoring may provide a more targeted, reliable approach for using antioxidant therapy in both research and practice.

Compared with hormonal EMT and ART, antioxidants are relatively safe, inexpensive and widely available, with a growing body of data supporting their effectiveness at improving semen parameters and live birth rates [53]. Further clinical studies are indicated to directly compare live birth rates among men with MOSI assigned to receive antioxidants *versus* EMT and ART. Treatment guidelines providing individualized antioxidant therapy protocols based on ORP status for men with MOSI could provide a significant advancement in the management of male factor infertility and facilitate future investigations (Fig. 6) [134]. Guidelines are also necessary to avoid possible overuse of antioxidants leading to reductive stress, which can be as detrimental to sperm health as OS [52,135-137] and has been associated with defects in embryogenesis [138]. Supra-physiologic levels of antioxidants may also scavenge the ROS necessary to induce sperm capacitation [32,38], leading to infertility. Because antioxidants are readily available online or over-the-counter, they may appear to be a benign first-line treatment. Without clear guidelines for appropriate use, however, there is a risk of overuse in men without evidence of MOSI who may then experience delay accessing more effective therapies (e.g., ART or varicocele repair). Therefore, the oxidative status of male infertility patients should be evaluated *before* antioxidants are recommended and used only in those cases where MOSI is present.

RECOMMENDATIONS AND FUTURE DIRECTIONS

Therefore, the authors recommend that men with idiopathic infertility should be screened for MOSI using an efficient, inexpensive, high sensitivity/specificity test for ORP such as MiOXSYS, which has practical advantages over alternative techniques (Table 1). Those men screening positive for MOSI should then undergo more extensive examination to identify treatable triggers and be counseled on appropriate steps to mitigate known causes of OS (e.g., smoking, alcohol consumption, lifestyle risk factors, radiation, toxins, etc.) [139,140]. ORP testing should be repeated no less

than 3 months following the appropriate management plan in infertile men with no explanation for MOSI. Ultimately, infertile men with MOSI should be advised to take antioxidants for a minimum of three months after other known causes of OS have been eliminated. Infertile men without MOSI should be advised against antioxidant therapy. Follow-up testing of ORP levels is recommended to confirm compliance and monitor the efficacy of antioxidant supplementation and continued lifestyle changes 6 to 8 weeks post treatment. We recommend that these approaches be tested in double blind randomized controlled trials to establish whether time to pregnancy and live birth rate is improved in couples where the man is undergoing antioxidant treatment.

With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, the development of evidence-based guidelines that target the underlying causes, while balancing the risks and benefits of individual therapies, is imperative. The authors feel that measurement of ORP and stratification of male fertility/infertility on the basis of ORP will be an important tool in the management of infertile couples. The exact role will be defined in future trials and could validate a reclassification of male infertility that incorporates MOSI as a diagnostic category. A better understanding of the etiology of this diagnosis will help identify those men likely to benefit from antioxidant therapy while minimizing the harmful effects of antioxidant overdosing.

ACKNOWLEDGEMENTS

The authors thank Ken Kula, Mary Reagan, and Bernastine Buchanan from the Center for Medical Art and Photography for assistance with the figures.

Financial support for this study was provided by the American Center for Reproductive Medicine.

Disclosure

None of the authors declares competing financial interests. The authors do not have any potential interest in promoting MiOXSYS.

Author Contribution

Conceptualization: AA. Writing—original draft: NP, AA,

MKPS. Writing—review & editing: all the authors.

REFERENCES

1. Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R, et al. Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. *Fertil Steril* 2013;99:1324-31.e1.
2. Kassa EM, Kebede E. Time-to-pregnancy and associated factors among couples with natural planned conception in Addis Ababa, Ethiopia. *Afr J Reprod Health* 2018;22:33-42.
3. Slama R, Hansen OK, Ducot B, Bohet A, Sorensen D, Giorgis Allemand L, et al. Estimation of the frequency of involuntary infertility on a nation-wide basis. *Hum Reprod* 2012;27:1489-98.
4. Juul S, Karmaus W, Olsen J. Regional differences in waiting time to pregnancy: pregnancy-based surveys from Denmark, France, Germany, Italy and Sweden. *Hum Reprod* 1999;14:1250-4.
5. Zinaman MJ, Clegg ED, Brown CC, O'Connor J, Selevan SG. Estimates of human fertility and pregnancy loss. *Fertil Steril* 1996;65:503-9.
6. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017. *Fertil Steril* 2017;108:393-406.
7. Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. *Fertil Steril* 2013;99:63.
8. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. *Hum Reprod Update* 2015;21:411-26.
9. Rutstein SO, Shah IH; ORC Macro; World Health Organization. Infecundity, infertility, and childlessness in developing countries. Calverton: World Health Organization; 2004.
10. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. *Reprod Biol Endocrinol* 2015;13:37.
11. World Health Organization. WHO laboratory manual for the examination and processing of human semen. Geneva: World Health Organization; 2010.
12. Irvine DS. Epidemiology and aetiology of male infertility. *Hum Reprod* 1998;13 Suppl 1:33-44.
13. O'Flynn O'Brien KL, Varghese AC, Agarwal A. The genetic causes of male factor infertility: a review. *Fertil Steril* 2010;93:1-12.
14. Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. *Reprod Biol Endocrinol* 2013;11:66.
15. Jurewicz J, Dziewirska E, Radwan M, Hanke W. Air pollution from natural and anthropic sources and male fertility. *Reprod Biol Endocrinol* 2018;16:109.
16. Punab M, Poolamets O, Paju P, Vihlajev V, Pomm K, Ladv R, et al. Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts. *Hum Reprod* 2017;32:18-31.
17. Tournaye H, Krausz C, Oates RD. Novel concepts in the aetiology of male reproductive impairment. *Lancet Diabetes Endocrinol* 2017;5:544-53.
18. Gabrielsen JS, Tanrikut C. Chronic exposures and male fertility: the impacts of environment, diet, and drug use on spermatogenesis. *Andrology* 2016;4:648-61.
19. Pasqualotto FF, Pasqualotto EB, Sobreiro BP, Hallak J, Medeiros F, Lucon AM. Clinical diagnosis in men undergoing infertility investigation in a university hospital. *Urol Int* 2006;76:122-5.
20. Chehab M, Madala A, Trussell JC. On-label and off-label drugs used in the treatment of male infertility. *Fertil Steril* 2015;103:595-604.
21. Jungwirth A, Diemer T, Kopa Z, Krausz C, Minhas S, Tournaye H. EAU guidelines on male infertility. Arnhem: European Association of Urology; 2018.
22. de Kretser DM. Male infertility. *Lancet* 1997;349:787-90.
23. Hamada A, Esteves SC, Agarwal A. Unexplained male infertility: potential causes and management. *Hum Androl* 2011;1:2-16.
24. Agarwal A, Durairajanayagam D, Halabi J, Peng J, Vazquez-Levin M. Proteomics, oxidative stress and male infertility. *Reprod Biomed Online* 2014;29:32-58.
25. Aitken RJ. Oxidative stress and the etiology of male infertility. *J Assist Reprod Genet* 2016;33:1691-2.
26. Bui AD, Sharma R, Henkel R, Agarwal A. Reactive oxygen species impact on sperm DNA and its role in male infertility. *Andrologia* 2018;50:e13012.
27. Agarwal A, Sharma RK, Nallella KP, Thomas AJ Jr, Alvarez JG, Sikka SC. Reactive oxygen species as an independent marker of male factor infertility. *Fertil Steril* 2006;86:878-85.
28. Tremellen K. Oxidative stress and male infertility: a clinical perspective. *Hum Reprod Update* 2008;14:243-58.
29. Aitken RJ, De Iuliis GN, Drevet JR. Role of oxidative stress in the etiology of male infertility and the potential therapeutic value of antioxidants. In: Henkel R, Samanta L, Agarwal A, editors. Oxidants, antioxidants, and impact of the oxidative status in male reproduction. London: Elsevier/Academic Press; 2018;91-100.

30. Wagner H, Cheng JW, Ko EY. Role of reactive oxygen species in male infertility: an updated review of literature. *Arab J Urol* 2017;16:35-43.
31. Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. *Urology* 1996;48:835-50.
32. Aitken RJ. Reactive oxygen species as mediators of sperm capacitation and pathological damage. *Mol Reprod Dev* 2017;84:1039-52.
33. Robinson JM. Phagocytic leukocytes and reactive oxygen species. *Histochem Cell Biol* 2009;131:465-9.
34. Aitken RJ, West K, Buckingham D. Leukocytic infiltration into the human ejaculate and its association with semen quality, oxidative stress, and sperm function. *J Androl* 1994;15:343-52.
35. Cassina A, Silveira P, Cantu L, Montes JM, Radi R, Sapiro R. Defective human sperm cells are associated with mitochondrial dysfunction and oxidant production. *Biol Reprod* 2015;93:119.
36. Agarwal A, Saleh RA, Bedaiwy MA. Role of reactive oxygen species in the pathophysiology of human reproduction. *Fertil Steril* 2003;79:829-43.
37. Du Plessis SS, Agarwal A, Halabi J, Tvrda E. Contemporary evidence on the physiological role of reactive oxygen species in human sperm function. *J Assist Reprod Genet* 2015;32:509-20.
38. O'Flaherty C. Redox regulation of mammalian sperm capacitation. *Asian J Androl* 2015;17:583-90.
39. Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczek J. The role of oxidative stress and antioxidants in male fertility. *Cent European J Urol* 2013;66:60-7.
40. Agarwal A, Cho CL, Esteves SC, Majzoub A. Reactive oxygen species and sperm DNA fragmentation. *Transl Androl Urol* 2017;6:S695-6.
41. Agarwal A, Ikemoto I, Loughlin KR. Relationship of sperm parameters with levels of reactive oxygen species in semen specimens. *J Urol* 1994;152:107-10.
42. Menezo Y, Evenson DP, Cohen M, Dale B. Effect of antioxidants on sperm genetic damage. In: Baldi E, Muratori M, editors. *Genetic damage in human spermatozoa*. New York: Springer; 2014;173-89.
43. Truong T, Gardner DK. Antioxidants improve IVF outcome and subsequent embryo development in the mouse. *Hum Reprod* 2017;32:2404-13.
44. Bisht S, Faiq M, Tolahunase M, Dada R. Oxidative stress and male infertility. *Nat Rev Urol* 2017;14:470-85.
45. Muratori M, Tamburrino L, Marchiani S, Cambi M, Olivito B, Azzari C, et al. Investigation on the origin of sperm DNA fragmentation: role of apoptosis, immaturity and oxidative stress. *Mol Med* 2015;21:109-22.
46. Aitken RJ. DNA damage in human spermatozoa; important contributor to mutagenesis in the offspring. *Transl Androl Urol* 2017;6:S761-4.
47. Agarwal A, Allamaneni SS. Free radicals and male reproduction. *J Indian Med Assoc* 2011;109:184-7.
48. Tremellen K. Treatment of sperm oxidative stress: a collaborative approach between clinician and embryologist. In: Henkel R, Samanta L, Agarwal A, editors. *Oxidants, antioxidants, and impact of the oxidative status in male reproduction*. London: Elsevier/Academic Press; 2018;225-35.
49. Agarwal A, Rana M, Qiu E, AlBunni H, Bui AD, Henkel R. Role of oxidative stress, infection and inflammation in male infertility. *Andrologia* 2018;50:e13126.
50. Shekarriz M, Thomas AJ Jr, Agarwal A. Incidence and level of seminal reactive oxygen species in normal men. *Urology* 1995;45:103-7.
51. Ochsendorf FR, Thiele J, Fuchs J, Schütttau H, Freisleben HJ, Buslau M, et al. Chemiluminescence in semen of infertile men. *Andrologia* 1994;26:289-93.
52. Henkel R, Sandhu IS, Agarwal A. The excessive use of anti-oxidant therapy: a possible cause of male infertility? *Andrologia* 2019;51:e13162.
53. Ross C, Morriss A, Khairy M, Khalaf Y, Braude P, Coomarasamy A, et al. A systematic review of the effect of oral antioxidants on male infertility. *Reprod Biomed Online* 2010;20:711-23.
54. Adewoyin M, Ibrahim M, Roszaman R, Isa MLM, Alewi NAM, Rafa AAA, et al. Male infertility: the effect of natural antioxidants and phytochemicals on seminal oxidative stress. *Diseases* 2017;5:E9.
55. Dada R, Shamsi MB, Venkatesh S, Gupta NP, Kumar R. Attenuation of oxidative stress & DNA damage in varicocelectomy: implications in infertility management. *Indian J Med Res* 2010;132:728-30.
56. Chen SS, Huang WJ, Chang LS, Wei YH. Attenuation of oxidative stress after varicocelectomy in subfertile patients with varicocele. *J Urol* 2008;179:639-42.
57. Agarwal A, Gupta S, Sharma R. Reactive oxygen species (ROS) measurement. In: Agarwal A, Gupta S, Sharma R, editors. *Andrological evaluation of male infertility: a laboratory guide*. Cham: Springer International Publishing; 2016;155-63.
58. Agarwal A, Roychoudhury S, Sharma R, Gupta S, Majzoub A, Sabanegh E. Diagnostic application of oxidation-reduction potential assay for measurement of oxidative stress: clinical utility in male factor infertility. *Reprod Biomed Online* 2017;34:48-57.

59. Agarwal A, Panner Selvam MK, Arafa M, Okada H, Homa S, Killeen A, et al. Multi-center evaluation of oxidation-reduction potential by the MiOXSYS System in males with abnormal semen. *Asian J Androl* 2019; In press.
60. Ko EY, Sabanegh ES Jr, Agarwal A. Male infertility testing: reactive oxygen species and antioxidant capacity. *Fertil Steril* 2014;102:1518-27.
61. Thonneau P, Marchand S, Tallec A, Ferial ML, Ducot B, Lansac J, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). *Hum Reprod* 1991;6:811-6.
62. Agarwal A, Virk G, Ong C, du Plessis SS. Effect of oxidative stress on male reproduction. *World J Mens Health* 2014;32:1-17.
63. Jarow J, Sigman M, Kolettis PN, Lipshultz LR, McClure RD, Nangia AK, et al. The optimal evaluation of the infertile male: AUA best practice statement reviewed and validity confirmed 2011. *Linthicum: American Urological Association*; 2011.
64. Esteves SC, Sharma RK, Gosálvez J, Agarwal A. A translational medicine appraisal of specialized andrology testing in unexplained male infertility. *Int Urol Nephrol* 2014;46:1037-52.
65. Patel AS, Leong JY, Ramasamy R. Prediction of male infertility by the World Health Organization laboratory manual for assessment of semen analysis: a systematic review. *Arab J Urol* 2017;16:96-102.
66. Wang C, Swerdloff RS. Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests. *Fertil Steril* 2014;102:1502-7.
67. Esteves SC, Zini A, Aziz N, Alvarez JG, Sabanegh ES Jr, Agarwal A. Critical appraisal of World Health Organization's new reference values for human semen characteristics and effect on diagnosis and treatment of subfertile men. *Urology* 2012;79:16-22.
68. Bonde JP, Ernst E, Jensen TK, Hjollund NH, Kolstad H, Henriksen TB, et al. Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners. *Lancet* 1998;352:1172-7.
69. Agarwal A, Sharma R, Roychoudhury S, Du Plessis S, Sabanegh E. MiOXSYS: a novel method of measuring oxidation reduction potential in semen and seminal plasma. *Fertil Steril* 2016;106:566-73.e10.
70. Samanta L, Agarwal A, Swain N, Sharma R, Gopalan B, Esteves SC, et al. Proteomic signatures of sperm mitochondria in varicocele: clinical use as biomarkers of varicocele associated infertility. *J Urol* 2018;200:414-22.
71. Arafa M, Agarwal A, Al Said S, Majzoub A, Sharma R, Bjugstad KB, et al. Semen quality and infertility status can be identified through measures of oxidation-reduction potential. *Andrologia* 2018;50:e12881.
72. Homa ST, Vassiliou AM, Stone J, Killeen AP, Dawkins A, Xie J, et al. A comparison between two assays for measuring seminal oxidative stress and their relationship with sperm DNA fragmentation and semen parameters. *Genes (Basel)* 2019;10:E236.
73. Okouchi S, Suzuki M, Sugano K, Kagamimori S, Ikeda S. Water desirable for the human body in terms of oxidation-reduction potential (ORP) to pH relationship. *J Food Sci* 2002;67:1594-8.
74. Grotto D, Santa Maria LD, Boeira S, Valentini J, Charão MF, Moro AM, et al. Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. *J Pharm Biomed Anal* 2007;43:619-24.
75. Vessey W, Perez-Miranda A, Macfarquhar R, Agarwal A, Homa S. Reactive oxygen species in human semen: validation and qualification of a chemiluminescence assay. *Fertil Steril* 2014;102:1576-83.e4.
76. Agarwal A, Roychoudhury S, Bjugstad KB, Cho CL. Oxidation-reduction potential of semen: what is its role in the treatment of male infertility? *Ther Adv Urol* 2016;8:302-18.
77. Agarwal A, Qiu E, Sharma R. Laboratory assessment of oxidative stress in semen. *Arab J Urol* 2017;16:77-86.
78. Agarwal A, Wang SM. Clinical relevance of oxidation-reduction potential in the evaluation of male infertility. *Urology* 2017;104:84-9.
79. Agarwal A, Arafa MM, Elbardisi H, Majzoub A, Alsaid SS. Relationship between seminal oxidation reduction potential and sperm DNA fragmentation in infertile men. *Fertil Steril* 2017;108:e316.
80. Agarwal A, Gupta S, Sharma R. Oxidation-reduction potential measurement in ejaculated semen samples. In: Agarwal A, Gupta S, Sharma R, editors. *Andrological evaluation of male infertility: a laboratory guide*. Cham: Springer International Publishing; 2016;165-70.
81. Majzoub A, Arafa M, Mahdi M, Agarwal A, Al Said S, Al-Emadi I, et al. Oxidation-reduction potential and sperm DNA fragmentation, and their associations with sperm morphological anomalies amongst fertile and infertile men. *Arab J Urol* 2018;16:87-95.
82. Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES Jr. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. *J Urol* 2012;187:973-8.
83. Kim HH, Schlegel PN. Endocrine manipulation in male infertility. *Urol Clin North Am* 2008;35:303-18.
84. Jung JH, Seo JT. Empirical medical therapy in idiopathic

- male infertility: promise or panacea? *Clin Exp Reprod Med* 2014;41:108-14.
85. Tadros NN, Sabanegh ES. Empiric medical therapy with hormonal agents for idiopathic male infertility. *Indian J Urol* 2017;33:194-8.
86. Nieschlag E, Kamischke A. Empirical therapies for idiopathic male infertility. In: Nieschlag E, Behre HM, Nieschlag S, editors. *Andrology: male reproductive health and dysfunction*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010;457-67.
87. Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. *Cochrane Database Syst Rev* 2013;CD005071.
88. Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence. *J Urol* 2006;176:1307-12.
89. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testosterone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. *J Androl* 1989;10:240-7.
90. Siddiq FM, Sigman M. A new look at the medical management of infertility. *Urol Clin North Am* 2002;29:949-63.
91. Mirończuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. *Adv Med Sci* 2018;63:68-78.
92. Halliwell B, Gutteridge JMC. Antioxidant defences synthesized in vivo. In: Halliwell B, Gutteridge JMC, editors. *Free radicals in biology and medicine*. 5th ed. Oxford: Oxford University Press; 2015.
93. Majzoub A, Agarwal A. Antioxidant therapy in idiopathic oligoasthenoteratozoospermia. *Indian J Urol* 2017;33:207-14.
94. Hsieh YY, Sun YL, Chang CC, Lee YS, Tsai HD, Lin CS. Superoxide dismutase activities of spermatozoa and seminal plasma are not correlated with male infertility. *J Clin Lab Anal* 2002;16:127-31.
95. Kobayashi T, Miyazaki T, Natori M, Nozawa S. Protective role of superoxide dismutase in human sperm motility: superoxide dismutase activity and lipid peroxide in human seminal plasma and spermatozoa. *Hum Reprod* 1991;6:987-91.
96. Ben Abdallah F, Dammak I, Attia H, Hentati B, Ammar-Keskes L. Lipid peroxidation and antioxidant enzyme activities in infertile men: correlation with semen parameter. *J Clin Lab Anal* 2009;23:99-104.
97. Lenzi A, Lombardo F, Gandini L, Culasso F, Dondero F. Glutathione therapy for male infertility. *Arch Androl* 1992;29:65-8.
98. Lenzi A, Culasso F, Gandini L, Lombardo F, Dondero F. Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility. *Hum Reprod* 1993;8:1657-62.
99. Atig F, Raffa M, Habib BA, Kerkeni A, Saad A, Ajina M. Impact of seminal trace element and glutathione levels on semen quality of Tunisian infertile men. *BMC Urol* 2012;12:6.
100. Dawson EB, Harris WA, Rankin WE, Charpentier LA, McGanity WJ. Effect of ascorbic acid on male fertility. *Ann N Y Acad Sci* 1987;498:312-23.
101. Akmal M, Qadri JQ, Al-Waili NS, Thangal S, Haq A, Saloom KY. Improvement in human semen quality after oral supplementation of vitamin C. *J Med Food* 2006;9:440-2.
102. Suleiman AA, Alboqai OK, Yasein N, Al-Essa MK, El Masri K. Prevalence of vitamin-mineral supplement use among Jordan University students. *Saudi Med J* 2008;29:1326-31.
103. Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell JM, Cooke ID, et al. A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. *Fertil Steril* 1995;64:825-31.
104. Nadjarzadeh A, Shidfar F, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, et al. Effect of coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. *Andrologia* 2014;46:177-83.
105. Tvrdá E, Peer R, Sikka SC, Agarwal A. Iron and copper in male reproduction: a double-edged sword. *J Assist Reprod Genet* 2015;32:3-16.
106. Zhao J, Dong X, Hu X, Long Z, Wang L, Liu Q, et al. Zinc levels in seminal plasma and their correlation with male infertility: a systematic review and meta-analysis. *Sci Rep* 2016;6:22386.
107. Ahsan U, Kamran Z, Raza I, Ahmad S, Babar W, Riaz MH, et al. Role of selenium in male reproduction: a review. *Anim Reprod Sci* 2014;146:55-62.
108. Ciftci H, Verit A, Savas M, Yeni E, Erel O. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. *Urology* 2009;74:73-6.
109. Oeda T, Henkel R, Ohmori H, Schill WB. Scavenging effect of N-acetyl-L-cysteine against reactive oxygen species in human semen: a possible therapeutic modality for male factor infertility? *Andrologia* 1997;29:125-31.
110. Stanislavov R, Rohdewald P. Sperm quality in men is improved by supplementation with a combination of L-arginine, L-citrullin, roburins and Pycnogenol®. *Minerva Urol Nefrol* 2014;66:217-23.
111. Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, random-

- ized, placebo-controlled trial. *Fertil Steril* 2002;77:491-8.
112. Castagné V, Lefèvre K, Natero R, Clarke PG, Bedker DA. An optimal redox status for the survival of axotomized ganglion cells in the developing retina. *Neuroscience* 1999;93:313-20.
113. Busetto GM, Agarwal A, Virmani A, Antonini G, Ragonesi G, Del Giudice F, et al. Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-asthenoteratozoospermia, with and without varicocele: a double-blind placebo-controlled study. *Andrologia* 2018;50.
114. Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. *J Urol* 2009;182:237-48.
115. Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. *Fertil Steril* 2005;84:662-71.
116. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. *J Urol* 2012;188:526-31.
117. ElSheikh MG, Hosny MB, Elshenoufy A, Elghamrawi H, Fayad A, Abdelrahman S. Combination of vitamin E and clomiphene citrate in treating patients with idiopathic oligoasthenozoospermia: a prospective, randomized trial. *Andrology* 2015;3:864-7.
118. Majzoub A, Agarwal A, Esteves SC. Antioxidants for elevated sperm DNA fragmentation: a mini review. *Transl Androl Urol* 2017;6:S649-53.
119. Micic S, Lalic N, Djordjevic D, Bojanic N, Bogavac-Stanojevic N, Busetto GM, et al. Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. *Andrologia* 2019;e13267. doi: <https://doi.org/10.1111/and.13267>
120. Balercia G, Buldregini E, Vignini A, Tiano L, Paggi F, Amoroso S, et al. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. *Fertil Steril* 2009;91:1785-92.
121. Tunc O, Thompson J, Tremellen K. Improvement in sperm DNA quality using an oral antioxidant therapy. *Reprod Biomed Online* 2009;18:761-8.
122. Tremellen K, Miari G, Froiland D, Thompson J. A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. *Aust N Z J Obstet Gynaecol* 2007;47:216-21.
123. Imamovic Kumalic S, Pinter B. Review of clinical trials on effects of oral antioxidants on basic semen and other parameters in idiopathic oligoasthenoteratozoospermia. *Biomed Res Int* 2014;2014:426951.
124. Lampiao F. Free radicals generation in an in vitro fertilization setting and how to minimize them. *World J Obstet Gynecol* 2012;1:29-34.
125. Bedaiwy MA, Falcone T, Mohamed MS, Aleem AA, Sharma RK, Worley SE, et al. Differential growth of human embryos in vitro: role of reactive oxygen species. *Fertil Steril* 2004;82:593-600.
126. Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. *Cochrane Database Syst Rev* 2014;CD007411.
127. Mora-Esteves C, Shin D. Nutrient supplementation: improving male fertility fourfold. *Semin Reprod Med* 2013;31:293-300.
128. Gil-Villa AM, Cardona-Maya W, Agarwal A, Sharma R, Cadavid A. Role of male factor in early recurrent embryo loss: do antioxidants have any effect? *Fertil Steril* 2009;92:565-71.
129. Calogero AE, Duca Y, Condorelli RA, La Vignera S. Male accessory gland inflammation, infertility, and sexual dysfunctions: a practical approach to diagnosis and therapy. *Andrology* 2017;5:1064-72.
130. La Vignera S, Vicari E, Condorelli RA, D'Agata R, Calogero AE. Male accessory gland infection and sperm parameters (review). *Int J Androl* 2011;34:e330-47.
131. Colpi GM, Francavilla S, Haidl G, Link K, Behre HM, Goulis DG, et al. European Academy of Andrology guideline Management of oligo-asthenoteratozoospermia. *Andrology* 2018;6:513-24.
132. Haidl G, Haidl F, Allam JP, Schuppe HC. Therapeutic options in male genital tract inflammation. *Andrologia* 2019;51:e13207.
133. Barratt CLR, Björndahl L, De Jonge CJ, Lamb DJ, Osorio Martini F, McLachlan R, et al. The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities. *Hum Reprod Update* 2017;23:660-80.
134. Atik RB, Christiansen OB, Elson J, Kolte AM, Lewis S, Middeldorp S, et al. ESHRE guideline: recurrent pregnancy loss. *Hum Reprod Open* 2018. doi: 10.1093/hropen/hoy002.
135. Henkel RR. Leukocytes and oxidative stress: dilemma for sperm function and male fertility. *Asian J Androl* 2011;13:43-52.
136. Gutteridge JM, Halliwell B. Antioxidants: molecules, medicines, and myths. *Biochem Biophys Res Commun* 2010;393:561-4.
137. Pérez-Torres I, Guarner-Lans V, Rubio-Ruiz ME. Reduc-

- tive stress in inflammation-associated diseases and the pro-oxidant effect of antioxidant agents. *Int J Mol Sci* 2017;18:E2098.
138. Ufer C, Wang CC, Borchert A, Heydeck D, Kuhn H. Redox control in mammalian embryo development. *Antioxid Redox Signal* 2010;13:833-75.
139. Hendin BN, Kolettis PN, Sharma RK, Thomas AJ Jr, Agarwal A. Varicocele is associated with elevated spermatozoal reactive oxygen species production and diminished seminal plasma antioxidant capacity. *J Urol* 1999;161:1831-4.
140. Harlev A, Agarwal A, Gunes SO, Shetty A, du Plessis SS. Smoking and male infertility: an evidence-based review. *World J Mens Health* 2015;33:143-60.

Appendix. Key terminologies

MOSI	Infertile men with abnormal semen characteristics and oxidative stress, which includes many patients who were previously classified as having idiopathic male infertility.
ROS	Reactive oxygen species (ROS) are compounds of oxygen radicals such as superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), hypochlorite ($OHCl$), and hydroxyl radical (OH) containing free, unpaired electrons in their outer orbit, which makes them highly unstable and reactive [57].
MiOXSYS	MiOXSYS is a novel technology used to measure oxidation-reduction potential (ORP) in semen based on a galvanostatic measure of electrons [58].
ORP	ORP is a measure of the relationship between oxidants and antioxidants that provides a comprehensive measure of the redox system. ORP cut-off value $1.34\text{ mV}/10^6\text{ sperm/mL}$ identified normal semen and abnormal semen quality with a sensitivity 98.1%, specificity 40.6%, positive predictive value 94.7% and negative predictive value 66.6% [59]. Indication of seminal ORP includes men with abnormal semen analysis and male infertility.
Oxidative stress	Oxidative stress occurs (OS) when there is an imbalance between ROS and the antioxidants that scavenge surplus free radicals [24].
Reductive stress	A shift of the bodily redox levels into a more reduced state is called reductive stress. Overdosing on antioxidants causes reductive stress [52].